Td Ameritrade Investment Management, LLC Bei Gene, Ltd. Transaction History

Td Ameritrade Investment Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $59,536 - $74,518	-331 Closed	0 $0
Q2 2023 Aug 09, 2023	SELL	$178.3 - $266.78 $16,047 - $24,010	-90 Reduced 21.38%	331 $59,000
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $18,104 - $23,058	-84 Reduced 16.63%	421 $91,000
Q4 2022 Feb 09, 2023	SELL	$125.51 - $229.3 $18,198 - $33,248	-145 Reduced 22.31%	505 $111,000
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $7,512 - $11,527	-57 Reduced 8.06%	650 $88,000
Q2 2022 Aug 09, 2022	SELL	$121.11 - $216.05 $11,626 - $20,740	-96 Reduced 11.96%	707 $114,000
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $66,520 - $122,380	454 Added 130.09%	803 $151,000
Q4 2021 Feb 11, 2022	BUY	$248.56 - $389.34 $49,712 - $77,868	200 Added 134.23%	349 $95,000
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $34,444 - $55,633	-138 Reduced 48.08%	149 $43,000
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $84,019 - $105,331	287 New	287 $98,000
Q4 2020 Feb 10, 2021	SELL	$221.31 - $316.61 $32,975 - $47,174	-149 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $28,187 - $42,679	149 New	149 $43,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Td Ameritrade Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Td Ameritrade Investment Management, LLC with notifications on news.